We must improve diversity in clinical trials. These 5 steps will help.

BioPharma Dive December 5, 2022
Sponsored content By Syneos Health

To better understand how medications impact the people who use them, participants in clinical trials should reflect real-life demographics. And yet, a U.S. Food and Drug Administration (FDA) analysis of clinical trials in 2020 found participants were largely homogenous and unrepresentative of the populations the healthcare industry serves: globally, 76% of enrolled participants were white, while just 11% were Asian and 7% were Black.¹ In the United States, 78% of enrolled participants were white while roughly 22% were people of color,¹ despite having a population nearly twice that number.²

These disparities could potentially hinder healthcare, says Angel Akinbinu, who is director for site and patient diversity with Syneos Health^®. “When we do not have diversity in our trials, we run...

Today's Sponsors

Today's Sponsor